神经生长因子及其受体在多巴胺激动剂耐受的垂体泌乳素腺瘤中的作用
|
摘要
第一部分
神经生长因子受体(NGFR)在垂体泌乳素腺瘤中的
表达及与肿瘤生物学特点的相关性研究目的探讨垂体泌乳素腺瘤中神经生长因子受体及增殖细胞核抗原(PCNA)表达与PRL腺瘤生物学特性之间的相关性。方法应用免疫组化方法检测38例垂体泌乳素腺瘤中两种神经生长因子受体及增殖细胞核抗原的表达情况,并根据肿瘤的生物学特点即侵袭性、多巴胺激动剂敏感性、性别、泌乳素水平、肿瘤大小进行分类。结果P75-NGFR的表达在侵袭性垂体腺瘤、高泌乳素水平,大腺瘤、多巴胺激动剂耐受的垂体腺瘤的表达明显要低于非侵袭性垂体腺瘤、低泌乳素水平,小腺瘤、多巴胺激动剂敏感的垂体腺瘤,而PCNA表达则明显要高,两者在各组中比较均具有显著性差异(p<0.05),而TrkA的表达在各组间没有明显差异;男性垂体泌乳素腺瘤PCNA表达明显要高于女性垂体腺瘤(p<0.05),而P75-NGFR及TrkA的表达在男性与女性垂体泌乳素腺瘤之间没有明显差异。结论P75NGFR的表达水平能间接反映垂体泌乳素腺瘤的增殖活性及对多巴胺受体激动剂的敏感性,P75NGFR有可能是某些腺瘤新的肿瘤生长抑制基因。
第二部分
神经生长因子(NGF)对GH3细胞增殖活性及细胞周期的影响
目的通过观察NGF对GH3细胞增殖及细胞周期及其受体表达的影响,探讨其诱导GH3细胞分化的机制。
方法应用MTT法、流式细胞仪、免疫组化法及western blot分别检测不同浓度NGF(10ng/ml、20ng/ml、50ng/ml和100ng/ml)对GH3细胞增殖的抑制情况、细胞周期的影响及两种多巴胺受体的表达情况。
结果不同浓度的NGF作用下均能抑制GH3细胞的增殖,使细胞S期明显减少,G0/G1比例增高,P75NGFR受体的表达明显增高,与对照组相比,差异有显著性,而TrkA受体在对照组中的表达与各实验组比较,无显著性差别。当NGF浓度为50ng/ml时,其抑制增殖效应,P75NGFR受体的表达量最高。
结论NGF可诱导GH3细胞分化,降低其增殖活性,S期比例降低,这可能与NGF诱导其P75NGFR受体的表达上调有关。
第三部分
神经生长因子(NGF)对GH3细胞PRL激素分泌活性及D2受体表达的影响
目的通过检测NGF应用后GH3细胞激素分泌活性及D2受体表达的改变,以更深入了解NGF对PRL腺瘤的作用机制。方法应用酶联免疫吸附实验检测了NGF应用前后对GH3细胞PRL激素分泌的改变,通过RT-PCR方法检测了NGF应用前后GH3细胞膜上D2受体的表达。结果单独应用NGF对GH3细胞PRL激素分泌抑制作用较小,联合应用NGF及
溴隐停较各单用组对PRL激素分泌抑制作用更加明显,(p<0.05)。
结论NGF可增强溴隐停对GH3细胞PRL激素分泌抑制作用,作用机制可能与
其诱导GH3细胞多巴胺D2受体的重新表达有关。
Part I Study of correlativity between the NGFR expression and the
biological characters in prolactin-secreting pituitary adenoma
Objective To explore the relationship between the expression of two receptors of nerve growth factor(NGF) , proliferation nuclear antigen (PCNA) and the biological characters of Prolactinomas. Methods The tumor specimens of 38 patients with prolactinoma was obtained by transsphenoid approach from 2003 to 2005.The expression of two receptors of nerve growth factor(NGF), Proliferation nuclear antigen (PCNA) was detected by immunohistochemistry methods. The patients were classified according to the invasion of surrounding structures or not, the volume of tumor, sex, the level of Prolactin secretion and the sensitivity to the dopamine agonist therapy. Results The expression of P75-NGFR was lower in invasive Prolactinomas , the tumor with high level of prolactin , macroadenomas , dopamine agonist -resistance adenomas than non-invasive Prolactinomas, the tumor with low level of prolactin , microadenomas, dopamine agonist-responsive adenomas respectively(p<0.05). The expression of was PCNA relatively higher, but the expression of another receptor of NGF (TrkA) is no differences between the each group. The PCNA in male prolactinomas was higher than that in female prolactinomas (p<0.05) and the two receptors of NGF were no difference between the male and female groups. Conclusions The expression of P75-NGFR could indirectly reflect the proliferation activity and the sensitivity to dopamine agonist therapy of the tumor. P75NGFR could be a novel tumor suppression gene of certain adenomas.
Part II The effect of proliferation activity and cell cycle in
GH3 cell treated by NGF
Objective To explore the mechanism of differentiation induced of by NGF administration in GH3 cell by observing the changes of proliferation, cell-cycle and the expression of its receptor. Methods The GH3 cell was treated by NGF with different concentrations, MTT was detected the proliferation of GH3 by NGF, and Flow cytometry was used for evaluating the cell cycle and the expression of two NGF receptors was detected by immunohistochemistry and western blot after NGF administration. Results The proliferating ability of GH3 cell was decreased by NGF, The GH3 cell showed the reduction of proportion of S phase and cell was arrested at G0/G1 phase. The expression of P75NGFR was up-regulated after NGF treatment. Comparing with the control group, All the effect at other groups were significantly different. The maximal inhibition effect of proliferation and the expression value of P75NGFR were achieved at 50ng/ml NGF. Conclusions NGF could induce the differentiation of GH3 cell into the more benign phenotype, the mechanism of reduction of proliferation and proportion of S phase after NGF treatment were probably due to the up-regulation the P75NGFR. Part III The effect of secretion activity of prolactin and expression of dopamine receptor-2 in GH3 cell treated by NGF
Objective To further investigate the mechanism treated by NGF through observing the changes of PRL secretion activity and the expression of dopamine receptor-2. Methods ELISA was measured for PRL basal secreting level and changes of its secreting level after administration the NGF and bromocriptine alone and combination, in GH3 cell. RT-PCR methods was detected the dopamine receptor-2 mRNA before and after administration the NGF. Results The inhibition effect of NGF on PRL secretion was little, and combination with bromocriptine could decrease the PRL secreting level obviously. Comparing with the other groups, the difference was statistically significant (p<0.05). The reexpression of dopamine receptor-2 mRNA was observed in GH3 cell treated by NGF and this effect was blocked by anti-NGF antibody. Conclusions NGF could enhance the inhibition effect of bromocriptine on PRL secretion, this action may be related to induction of the reexpression of dopamine receptor-2.
神经生长因子受体(NGFR)在垂体泌乳素腺瘤中的
表达及与肿瘤生物学特点的相关性研究目的探讨垂体泌乳素腺瘤中神经生长因子受体及增殖细胞核抗原(PCNA)表达与PRL腺瘤生物学特性之间的相关性。方法应用免疫组化方法检测38例垂体泌乳素腺瘤中两种神经生长因子受体及增殖细胞核抗原的表达情况,并根据肿瘤的生物学特点即侵袭性、多巴胺激动剂敏感性、性别、泌乳素水平、肿瘤大小进行分类。结果P75-NGFR的表达在侵袭性垂体腺瘤、高泌乳素水平,大腺瘤、多巴胺激动剂耐受的垂体腺瘤的表达明显要低于非侵袭性垂体腺瘤、低泌乳素水平,小腺瘤、多巴胺激动剂敏感的垂体腺瘤,而PCNA表达则明显要高,两者在各组中比较均具有显著性差异(p<0.05),而TrkA的表达在各组间没有明显差异;男性垂体泌乳素腺瘤PCNA表达明显要高于女性垂体腺瘤(p<0.05),而P75-NGFR及TrkA的表达在男性与女性垂体泌乳素腺瘤之间没有明显差异。结论P75NGFR的表达水平能间接反映垂体泌乳素腺瘤的增殖活性及对多巴胺受体激动剂的敏感性,P75NGFR有可能是某些腺瘤新的肿瘤生长抑制基因。
第二部分
神经生长因子(NGF)对GH3细胞增殖活性及细胞周期的影响
目的通过观察NGF对GH3细胞增殖及细胞周期及其受体表达的影响,探讨其诱导GH3细胞分化的机制。
方法应用MTT法、流式细胞仪、免疫组化法及western blot分别检测不同浓度NGF(10ng/ml、20ng/ml、50ng/ml和100ng/ml)对GH3细胞增殖的抑制情况、细胞周期的影响及两种多巴胺受体的表达情况。
结果不同浓度的NGF作用下均能抑制GH3细胞的增殖,使细胞S期明显减少,G0/G1比例增高,P75NGFR受体的表达明显增高,与对照组相比,差异有显著性,而TrkA受体在对照组中的表达与各实验组比较,无显著性差别。当NGF浓度为50ng/ml时,其抑制增殖效应,P75NGFR受体的表达量最高。
结论NGF可诱导GH3细胞分化,降低其增殖活性,S期比例降低,这可能与NGF诱导其P75NGFR受体的表达上调有关。
第三部分
神经生长因子(NGF)对GH3细胞PRL激素分泌活性及D2受体表达的影响
目的通过检测NGF应用后GH3细胞激素分泌活性及D2受体表达的改变,以更深入了解NGF对PRL腺瘤的作用机制。方法应用酶联免疫吸附实验检测了NGF应用前后对GH3细胞PRL激素分泌的改变,通过RT-PCR方法检测了NGF应用前后GH3细胞膜上D2受体的表达。结果单独应用NGF对GH3细胞PRL激素分泌抑制作用较小,联合应用NGF及
溴隐停较各单用组对PRL激素分泌抑制作用更加明显,(p<0.05)。
结论NGF可增强溴隐停对GH3细胞PRL激素分泌抑制作用,作用机制可能与
其诱导GH3细胞多巴胺D2受体的重新表达有关。
Part I Study of correlativity between the NGFR expression and the
biological characters in prolactin-secreting pituitary adenoma
Objective To explore the relationship between the expression of two receptors of nerve growth factor(NGF) , proliferation nuclear antigen (PCNA) and the biological characters of Prolactinomas. Methods The tumor specimens of 38 patients with prolactinoma was obtained by transsphenoid approach from 2003 to 2005.The expression of two receptors of nerve growth factor(NGF), Proliferation nuclear antigen (PCNA) was detected by immunohistochemistry methods. The patients were classified according to the invasion of surrounding structures or not, the volume of tumor, sex, the level of Prolactin secretion and the sensitivity to the dopamine agonist therapy. Results The expression of P75-NGFR was lower in invasive Prolactinomas , the tumor with high level of prolactin , macroadenomas , dopamine agonist -resistance adenomas than non-invasive Prolactinomas, the tumor with low level of prolactin , microadenomas, dopamine agonist-responsive adenomas respectively(p<0.05). The expression of was PCNA relatively higher, but the expression of another receptor of NGF (TrkA) is no differences between the each group. The PCNA in male prolactinomas was higher than that in female prolactinomas (p<0.05) and the two receptors of NGF were no difference between the male and female groups. Conclusions The expression of P75-NGFR could indirectly reflect the proliferation activity and the sensitivity to dopamine agonist therapy of the tumor. P75NGFR could be a novel tumor suppression gene of certain adenomas.
Part II The effect of proliferation activity and cell cycle in
GH3 cell treated by NGF
Objective To explore the mechanism of differentiation induced of by NGF administration in GH3 cell by observing the changes of proliferation, cell-cycle and the expression of its receptor. Methods The GH3 cell was treated by NGF with different concentrations, MTT was detected the proliferation of GH3 by NGF, and Flow cytometry was used for evaluating the cell cycle and the expression of two NGF receptors was detected by immunohistochemistry and western blot after NGF administration. Results The proliferating ability of GH3 cell was decreased by NGF, The GH3 cell showed the reduction of proportion of S phase and cell was arrested at G0/G1 phase. The expression of P75NGFR was up-regulated after NGF treatment. Comparing with the control group, All the effect at other groups were significantly different. The maximal inhibition effect of proliferation and the expression value of P75NGFR were achieved at 50ng/ml NGF. Conclusions NGF could induce the differentiation of GH3 cell into the more benign phenotype, the mechanism of reduction of proliferation and proportion of S phase after NGF treatment were probably due to the up-regulation the P75NGFR. Part III The effect of secretion activity of prolactin and expression of dopamine receptor-2 in GH3 cell treated by NGF
Objective To further investigate the mechanism treated by NGF through observing the changes of PRL secretion activity and the expression of dopamine receptor-2. Methods ELISA was measured for PRL basal secreting level and changes of its secreting level after administration the NGF and bromocriptine alone and combination, in GH3 cell. RT-PCR methods was detected the dopamine receptor-2 mRNA before and after administration the NGF. Results The inhibition effect of NGF on PRL secretion was little, and combination with bromocriptine could decrease the PRL secreting level obviously. Comparing with the other groups, the difference was statistically significant (p<0.05). The reexpression of dopamine receptor-2 mRNA was observed in GH3 cell treated by NGF and this effect was blocked by anti-NGF antibody. Conclusions NGF could enhance the inhibition effect of bromocriptine on PRL secretion, this action may be related to induction of the reexpression of dopamine receptor-2.
引文
1．王忠诚．神经外科学．第一版，武汉：湖北科学技术出版社，1998：489
2. Melmed S. Pathogenesis of pituitary tumors [J]. Endocrinol Metab Clin North Am, 1999, 28:1-12.
3. Missale C, Fiorentini C, Finardi, et al. Growth factors in pituitary tumors. Pituitary, 1999, 1:153-158.
4．张龙，雷霆，薛德麟．EGF、TGF-α及其受体在垂体瘤中的表达．癌症，2000，19：944
5. Heaney AP, Horwitz GA, Wang Z, et al. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis [J]. Nat Med, 1999, 5: 1317-1321.
6. Zhang X, Horwitz GA, Prezant TR, et al. Structure, expression and function of human pituitary tumor transforming gene (PTTG) [J]. Mol Endocrinol, 1999, 13: 156-166.
7．郭常利，吴瑜，王兰，等．PCNA、P16、TGF-β1蛋白表达与垂体腺瘤侵袭性的关系．中国临床神经科学，2001，9：237-239．
8. Levi-Montalcini R. The nerve growth factor 35 years later[J]. Science, 1987, 237: 1154-1162.
9. Patterson JC, Childs GW. Nerve growth factor and its receptors in the anterior pituitary. Endocrinology, 1994, 135: 1689-1696.
10. Missale C, Boroni F, Sigala S, et al. Nerve growth factor in the anterior pituitary: Localization in mammotroph cells and cosecretion with prolactin by a dopamine-regulated mechanism. Pro Natl Acad Sci, 1996, 93:4240-4245.
11. Burnham P, Conner JM, Varon S, et al. Colocalization of NGF and TSH-like immunoreactivity in cultures of adult rat anterior pituitary cells. J Neurosci Res, 1995, 41:73-78.
12. Baker DL, Molemaar WM, Trojanowski JQ, et al. Nerve growth factor receptor in peripheral and central neuroectodermal tumors, other pediatric brain tumors and during development of the adrenal gland. Am J Pathol, 1991,139: 115-122.
13. Azar C, Scavarda NJ, Reynolds CP, et al. Multiple defects of the nerve growth factor receptor in human neuro-blastomas. Prog Clin Biol Res, 1991, 366:219-226.
14. Frade JM, Rodriguez-Tebar A, Barde YA. Induction of cell death by endogenous NGF through its P75 receptor [J]. Nature, 1996,383:166.
15. Zhu ZW, Friess H, Fabio F, et al. Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer. J Clin Oncol, 1999, 17: 2419-2428.
16. Sortino MA, Condorelli F, Vancheri C et al. Mitogenic effect of nerve growth factor (NGF) in LNCaP prostate adenocarcinoma cells: Role of the high-and low-affinity NGF receptors. Mol Endocrinol, 2000, 14: 124-136.
17. Zhu ZW, Friess H, Wang L, et al. Down-Regulation of nerve growth factor in poorly differentiated and advanced human esophageal cancer. Anti-cancer Research, 2000,20: 125-132.
1．王忠诚主编．神经外科学[M]．第一版．武汉：湖北科技出版社，1998，489．
2. Soule SG, Powell M, Jacobs HS. Prolactinomas resistant to dopamine agonists: Insights into pathogensis and therapy. Curt Opin Obstet Gynecol, 1994, 6:393-397.
3．张作洪，朱炎昌，雷霆．神经生长因子受体在垂体腺瘤中的表达．临床与实验病理学杂志，2000，16 28-30．
4．张达青，胡绍文主编．下丘脑-垂体疾病[M]．北京：科学技术文献出版社，2001，443．
5. Knosp E, Steiner E, Kitz K, et al. Pituitary adenomas with invasive of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery, 1993, 33: 610-617.
6. Meij BP, Lopes MB, Ellegala DB, et al. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery[J]. J neurosurg 2002, 96:195-208.
7. Levi-Montalcini R. The nerve growth factor 35 years later[J]. Science, 1987, 237: 1154-1162.
8. Klein R, Jing S, Nanduri V et al. The trk Proto-oncogene encodes a receptor for nerve growth factor. Cell, 1991; 65:189-197.
9. Hempstead BL, Martin-Zanca D, Kaplan DR, et al. High-affinity NGF binding requires coexpression of the trk protooncogene and Low-affinity NGF receptor. Nature (Lond), 1991, 350:678～683.
10. Maliartchouk S, Saragovi U. Optimal nerve growth factor trophic signals mediated by synergy of trkA and p75 receptor specific ligands. J Neurosci, 1997, 17:6031～6037.
11．郭丽英，周元聪．神经生长因子与细胞凋亡．生命的化学，1999；2：56～58．
12．张龙，雷霆，薛德麟．垂体瘤中EGF TGF-α及其受体的表达．中国肿瘤临床，2000；27：805-806．
13. Fukui S, Otani N, Nawashiro H, et al. Nuclear accumulation of basic fibroblast growth factor as a predictor for the recurrence of pituitary adenomas. J Neurooncol, 2002, 57:221-9.
14．张雪宝，陆天才，李锋，等．神经生长因子及其受体在宫颈原位癌中的表达．临床与实验病理学杂志，2003；19：145-148．
15. Krygiet s, Djakiew D. Neurotrophin recepotr p75(NTR) suppresses growth and nerve growth factor-mediated metastasis of human prostate cancer cells. Int J Cancer, 2002, 98:1-7.
16. Van Dierendonck JK, Wijsman JH, Keijzer R, et al. Cell cycle-related staining patterns of anti-proliferating cell nuclear antigen monoclonal antibodies. Am J Pathol, 1991, 138:1165-1172.
17. Hsu DW, Hakim F, Biller BMK, et al. significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence [J]. J neurosurg, 1993, 78:753-761.
18. Thaper K, Kovacs KT, Scheithauer BW, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-I antibody [J]. Neuro surgery, 1996, 38:99-107.
19. Molitch ME, Elton RL, Blackwell RE, et al. Bromocriptine as primary therapy for prolactin-secting macroadenomas: Results of a prospective multi-center study. J Clin Endocrinol Metab, 1985, 60:698.
20．张作洪，朱炎昌，雷霆．神经生长因子受体在垂体腺瘤中的表达．临床与实验病理学杂志，2000，16：28-30．
21. Pellegrini I, Rasolonjanahary R, Gunz G, et al. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab, 1989, 69:500-509.
22. Dinicola AF. Letter: Nerve growth factor and neuroblastoma. J Pediatr, 1976, 89: 517.
23. Watanable T, Katayama Y, Kimura S, et al. Control of proliferation and survival of C6 glioma cells with modification of the nerve growth factor autocrine system. J Neurooncol, 1999,41:121-128.
24. Missale C, Boroni F, Losa M, et al. Nerve growth factor suppresses the transforming phenotype of human prolactinomas. Prac Natl Acad Sci, 1993, 90:7961-7965.
25. Dobrowsky RT, Wether MH, Castellino AM, et al. Activation of the sphingomyelin cycle through the low affinity neurotrophin receptor. Science 265:1596-1599.
26. Kim M-Y, Linardic C, Obeid L, et al. Identification of sphingomyelin tumover as an effector mechanism for the action of tumor necrosis factor alpha and gamma interferon. J Biol Chem, 266:484-489.
27. Obeid LM, Linardic CM, Karolak LA, et al. Programmed cell death induced by ceramide. Science, 259:1769-1771.
28. Sigala S, Faraoni I, Botticini D, et al. Suppression of telomerase, reexpression of KAI1, and abrogation of tumorigenicity by nerve growth factor in prostate cancer cell lines. Clin Cancer Res. 1999, 5:1211-8.
29．张继红，李爱敏，张锦华．激活NGF／trkA信号传导通路引起NB细胞良性分化的研究．肿瘤防治杂志，2004，11：897-912．
1. Prasad KN, Hovland AR, Nahreini P, et al. Differentiation genes: are they primary targets for human carcinogenesis? Exp Biol Med, 2001, 226: 805-813.
2. Leszczyniecka M, Roberts T, Dent P, et al. Differentiation therapy of human cancer: basic science and clinical applications. Pharmacol Ther, 2001, 96: 1556-1561.
3. Anderson DJ. Molecular control of cell fate in neural crest: the sympathoadenal lineage. Annu Rev Neurosci, 1993, 16: 129-158.
4. Greene LA and Tischler AS. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor[J]. PNAS, 1976, 73: 2424-2428.
5. Yaeger MJ, Koestner A, Marushige K, et al. The reverse transforming effect of nerve growth factor on five human neurogenic tumor lines: in vitro results. Acta Neuropathol, 1991, 83:72～80
6. Mitchner NA, Garlick C, Steimnetz RW, et al. Differential regulation and action of estrogen receptors alpha and beta in GH3 cells. Endocrinology, 1999, 140: 2651-2658.
7. Missale C, Boroni F, Sigala S, et al. Nerve growth factor directs differentiation of the bipotential cell line GH3 into the mammotroph phenotype. Endocrinology, 1994, 135:220-228.
8．吴楠，查锡良．肿瘤细胞的诱导分化．生命的化学，2004，24：496-499．
9．汤钊猷主编．现代肿瘤学．肿瘤逆转．第1版．上海：上海医科大学出版社，1993．157-167
10. Kovacs K, Stefaneanu L, Horvath E, et al. Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy, Case report. J Neurosurg, 1995, 82: 886-890.
11. Missale C, Boroni F, Losa M, et al. Nerve growth factor suppresses the transforming phenotype of human prolactinomas. Proc Natl Acad Sci, 1993, 7961-7965.
12．高强，董倩，吕振华，等．转神经生长因子基因诱导神经母细胞瘤分化的研究．中华小儿外科杂志，2005，26：34-37．
13. Marushige Y, Marushige K, Koestner A. Growth inhibition of anaplastic glioma cells by nerve growth factor. Anticancer Res, 1992, 12: 2069-2073.
14．初明，胡志强，魏兰兰，等．白黎芦醇对垂体腺瘤GH3细胞生长及其分子机制的研究．中华医学杂志，2003，83：2004-2006．
15．李秋营，宋补昌，姚汝琳，MTT还原法与BrdU标记法检测2BS增殖活性比较．山西医科大学学报，2002，33：79-80．
16. Pestell RG, Albanese C, Reutens AT, et al. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocrine Rev, 1999, 20: 501-534.
17. Missale C, Codignola A, Sigala S, et al. Nerve growth factor abroagates the tumorigenicity of human small cell lung cancer cell lines. Proc Natl Acad Sci, 1998, 95: 5366-5371.
18. Miyasaka T, Sternberg DW, Miyasaka J, et al. Nerve growth factor stimulates protein tyrosine phosphorylation in PC-12 pheochromocytoma cells. Proc Natl Acad Sci, 1991, 88: 2653-2663.
19．关新民主编．医学神经生物学，第三章：受体，北京：人民卫生出版社，2002，63-65．
20. Walch ET, Marchetti D. Role of neurotrophins and neurotrophins receptors in the in vitro invasion and heparanase production of human prostate cancer cells. Clin Exp Metastasis. 1999, 17: 307-314.
21. Zhu ZW, Friess H, Wang L, et al. Nerve growth factor exerts differential effects on the growth factor as a mitogen for a pancreaticcancer cells. Clin Cancer Res, 2001, 7: 105-112.
22．佟海侠．神经营养因子及其受体在神经母细胞瘤中的作用．国外医学儿科学分册，2000，27：65-68．
23．折晓宁，陈杰，刘彤华，等．高亲和性神经生长因子受体对神经生长因子诱导 神经母细胞瘤细胞分化的影响．中华病理学杂志，2000，29：196-199．
24. Brann AB, Scott R, Neuberger Y, et al. Ceremide signaling downstream P75 neurotrophin receptor mediates the effects of nerve growth factor on outgrowth of cultured hippocampal neurons. J Neurosci, 1999, 19:8199-8206.
25. Encinas M, Iglesias M, Llecha N, et al. Extracellular-regulated kinases and phosphatidylinositol 3-kinase are involved in brain-derived neurotrophic factor-mediated survival and neuritogenesis of the neuroblastoma cell line SH-SY5Y. J Neurochem, 1999, 73:1409-1421.
1. Molitch ME. Disorders of prolatin section. Endocrinol Metab Clin NAmer, 2001, 30:585-610.
2. Decamilli P, Macconi D, Spada A, et al. Dopamine inhibits adenylate cyclase in human prolactin-secreting pituitary adenomas. Nature, 1979, 278:252-254.
3. Soule SG, Powell M, Jacobs HS. Prolactinomas resistant to dopamine agonists: insights into pathogenesis and therapy. Curr opin Obstet Gynecol, 1994, 6:393-397.
4. Monsma FJ, McVittie LD, Gerfen CR, et al. Multiple D2 dopamine receptors produced by alternative RNA splicing. Nature, 1989, 342:926-929.
5. Senogles SE. The D2 dopamine receptor isoforms signal through distinct Giα proteins to inhibit adenylyl cyclase. J Biol Chem, 1994, 269:23120-23127.
6. Vallar L, Vicentini LM, Meldolesi J, et al. Inhibition of inositol phosphate production is a late, Ca~(2+)-dependent effect of D2 dopaminergic receptor activation in rat lactotroph cells. J Biol Chem, 1988, 263:10127-10134.
7. Iaccarino C, Samad TA, Mathis C, et al. Control of lactotroph proliferation by dopamine: essential role of signaling through D2 receptors and ERKS. PNAS, 2002, 99:14530-14535.
8. Molitch ME. Dopamine resistance of prolactinomas. Pituitary, 2003, 65:19-27.
9. Kanasaki H, Fukunaga K, Takahashi, et al. Involvement of Mitogen-actived protein kinase activation in bromocriptine-induced apoptosis in rat GH3 cells. Biol of Reproduction, 2000, 62:1486-1494.
10. Missale C, Castelletti L, Boroni F, et al. Epidermal growth factor induces the functional expression of dopamine receptors in the GH3 cell line. Endocrinology. 1991, 128:13-20.
11. Pellegrini-Bouiller I, Morange-Ramos I, Barlier A, et al. Pit-1 gene expression in human lactotroph and somatotroph pituitary adenomas is correlated to D2 receptor gene expression. J Clin Endocrinol Metab. 1996, 81: 3390-6.
12．张作洪，朱炎昌，雷霆．神经生长因子受体在垂体腺瘤中的表达．临床与实验病理学杂志，2000，16：28-30．
13. Scillitani A, Dicembrino F, Di Fazio P, et al. In vivo visualization of pituitary dopaminergic receptors by iodine-123 methoxybenzamide (IBZM) correlates with sensitivity to dopamine agonists in two patients with macroprolactinomas. J Clin Endocrinol Metab, 1995, 80: 2523-2525.
14. Missale C, Nash SR, Robinson S, et al. Dopamine receptors: from structure to function. Physiol Rev, 1998, 78: 189-225.
15. Guivarc'h D, Vincent JD, Vernier P, et al. Alternative splicing of the D2 dopamine receptor messenger ribonucleic acid is modulated by activated sex steroid receptors in the MMQ prolactin cell line. Endocrinology. 1998, 139:4213-4221.
16. Missale C, Losa M, Sigala S, et al. Nerve growth factor controls proliferation and progression of human prolactinoma cell lines through an autocrine mechanism. Mol Endocrinol., 1996, 10: 272-85.
17. Yoon SO, Casaccia-Bonnefil P, Carter B, et al. Competitive signaling between TrkA and p75 nerve growth factor receptors determines cell survival. J Neurosci, 1998, 18: 3273-81
18．尹方明．P75和TrkA：两种NGF受体系．国外医学神经病学神经外科学分册，1997．24：205-208．
1. Soule SG, Powell M, Jacobs HS. Prolactinomas resistant to dopamine agonists: Insights into pathogensis and therapy. Curr Opin Obstet Gynecol, 1994, 6:393-397.
2. Friedman E, Adams EF, Hoog A, et al Normal structural dopamine type 2 receptor gene in prolactin-secreting and other pituitary tumors. J Clin Endocrinol Metab, 1994, 78(3): 568-74.
3. Liu JC, Baker RE, Sun C, et al. Activation of Go-coupled dopamine D_2 receptors inhibits ERK1/ERK2 in pituitary cells. A key step in the transcriptional suppression of the prolactin gene. J Biol Chem, 2002, 277:35819-35825.
4. Mark E., Molitch. Dopamine resistance of prolactinomas. Pituitary, 2003, 6:19-27.
5. Cannavo S, Bartolone L, Blandino A, et al. Shinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline. J Endocrinol Invest, 1999, 22: 306-309.
6. Delgrange E, Crabbe J, Donckier J. Late development of resistance to bromocriptine in a patient with macroprolactinoma. Horm Res, 1998, 49:250-253.
7. Hurel SJ, Haris PE, Mcnicol AM, et al. Metastatic prolactinoma: effect of octreotide, cabergoline, carboplactin and etoposide; immunocytochemical analysis of proto-oncogene expression. J Clin Endocrinol Metab, 1997,79:2962-2965.
8. Webster J, Piscitelli G, Polli A,et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med, 1994, 331: 904-909.
9. DiSarno A, Landi ML, Cappabianca P, et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: Prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab, 2001,86: 5256-5261.
10. Freda PU, Andreadis CI, Knandji AG, et al. Long-term treatment of prolactin-secreting macroadenomas with pergolide. J Clin Endocrinol Metab, 2000, 85:8-13.
11.Colao A, DiSarno A, Landi ML, et al. Macroprolactinoma shinkage during cabergoline treatments is greater in naive patients than in patients pretreated with other dopamine agonists: A prospective study in 110 patients. J Clin Endocrinol Metab, 2000, 85: 2246-2252.
12. Pellegrini I, Rasolonjanahary R, Gunz G, et al. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab, 1989, 69: 500-509.
13. Caccavelli L, Feron F, Morange I, et al. Decreased expression of the two D_2 dopamine receptor isoforms in bromocriptine-resistance prolactinoma. Neuroendocrinol, 1994, 60:314-322.
14. Caccavelli L, Morange-Ramos I, Kordon C, et al. Alteration of Ga subunits mRNA levels in bromocriptine-resistant adenomas. J Neuroendocrinol, 1996, 8:737-746.
15. Colao A, DiSarno A, Samacchiaro F, et al. Prolactinoma resistant to standard dopamine agonists respond to chronic cabergolione treatment. J Clin Endocrinol Metab, 1997, 82:876-883.
16. Lamberts S, Verleun T, Hofland L, et al. Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells. J Clin Endocrinol Metab. 1986, 63: 1342-1347.
17. Prior JC, Cox TA, Fairholm D, et al. Testosterone-related exacerbation of a prolactin-producing macroadenoma: Possible role for estrogen. J Clin Endocrinol Metab, 1987,64,391 -394.
18. Missale C, Boroni F, Losa M, et al. Nerve growth factor suppresses the transforming phenotype of human prolactinomas. Prac Natl Acad Sci, 1993, 90:7961-7965.
19. Missale C, Losa M, Boroni F, et al. Nerve growth factor and bromocriptine: A sequential therapy for human bromocriptine-resistant prolactinomas. Brit J Cancer, 1995,72: 1397-1399.
20. Fiorentini C, Guerra N, Facchetti M, et al. Nerve growth factor regulates dopamine D2receptor expression in prolactinoma cell lines via p75 -mediated activation of nuclear factor-κB. Mol Endocrinol, 2002, 16: 353-366.
1. Spada A, Lania A. Growth factors and human pituitary adenoma. Mol Cell Endocrinol. 2002, 197:63-68.
2. Chaidarun SS, Eggo MC, Sheppard MC, et al. Expression of epidermal growth factor (EGF), its receptor, and related oncoprotein (erbB-2) in human pituitary tumors and response to EGF in vitro. Endocrinology, 1994, 135:2012-2021.
3. Onguru O, Scheithauer BW, Kovacs K, et al. Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas. Mol Pathol, 2004, 17:772-780.
4. LeRiche VK, Asa SL, Ezzat SJ, et al. Epidermal growth factor and its receptor (EGFR) in human pituitary adenomas: EGFR correlates with tumor aggressiveness. Clin Endocrinol Metab, 1996, 81: 656-662.
5. Theodoropoulou M, Arzberger T, Gruebler Y, et al. Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells. J Endocrinol, 2004, 183: 385-394.
6．张龙，雷霆，薛德麟．表皮生长因子及染料木黄酮对垂体瘤细胞增殖的调节．同济医科大学学报，2001，30：131-133．
7. McCabe CJ, Khaira JS, Boelaert K, et al. Expression of pituitary tumor transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumor behaviour. Clin Endocrinol, 2003, 58:141-150.
8. Fukui S, Otani N, Nawashiro H, et al. Nuclear accumulation of basic fibroblast growth factor as a predictor for the recurrence of pituitary adenomas. J Neurooncol, 2002, 57: 221-229.
9．文路，陈凌，刘运生．碱性成纤维细胞生长因子与垂体腺瘤增殖及侵袭能力的关系．湖南医科大学学报，2001，26：466-468．
10. Fukui S, Otani N, Nawashiro H, et al. Subcellular localization of basic fibroblast growth factor and fibroblast growth factor receptor-1 in pituitary adenomas. Brain Tumor Pathol. 2002, 19: 23-29.
11. Crnauer MV, Schulz WA, Seifert HH, et al. Fibroblast growth factors and their receptors in urological cancers: basic research and clinical implications. Eur Urol, 2003, 43: 309-319.
12. Mignatti P, Morimoto T, Rifkin DB, et al.. In vitro angiogenesis on the human amniotic membrane: requirement of basic fibroblast growth factor induced proteinases [J]. J Cell Biol, 1989, 108:617 - 682.
13. Kawamoto H, Uozumi T, Kawamoto K, et al. Type Ⅳ collagenaseactivity and cavernous sinus invasion in human pituitary adenomas [J]. Acta Neurochir (Wien), 1996, 138: 390-395.
14. Sakarnoto H, Mori M, Taria M, et al. Transforming gene frorn human stomch cancers and a noncancerous portion of stomach mucosa [J]. Proc Natl Acad Sci, 1986, 83: 3997-4001.
15．郭常利，吴瑜，王兰，等．PCNA、P16、TGF-β1蛋白表达与垂体腺瘤侵袭性的关系．中国临床神经科学，2001，9：237-239．
16．王连刚，王喜青，武毅军等．表皮生长因子、转化生长因子-α及其受体在人垂体腺瘤组织中的表达，细胞与分子免疫学杂志，2000，16：156-158．
17. McAndrew J, Paterson AJ, Asa SL,. et al. Targeting of transforming growth factor-alpha expression to pituitary lactotrophs in transgenic mice results in selective lactotroph proliferation and adenomas. Endocrinology, 1995,136: 4479-4488.
18. Ramsdell JS. Transforming growth factor-alpha and-beta are potent and effective inhibitors of GH4 pituitary tumor cell proliferation. Endocrinology, 1991, 128: 1981-1990.
19. Fukui S, Otani N, Nawashiro H, et al. The association of the expression of vascular endothelial growth factor with the cystic component and haemorrhage in pituitary adenoma. J Clin Neurosci, 2003, 10: 320-324.
20．沈晓黎，雷霆，万锋，等．VEGF及其受体KDR在垂体腺瘤中的表达与肿瘤血管形成的关系．肿瘤防治研究，2005，32：8-10．
21. Lohrer P, Gloddek J, Hopfner U, et al. Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro. Neuroendocrinology, 2001, 74: 95-105.
22. Missale C, Boroni F, Sigala S, et al. Nerve growth factor in the anterior pituitary: localization in mammotroph cells and cosecretion with prolactin by a dopamine-regulated mechanism. Pro Natl Acad Sci, 1996, 93:424-425.
23．张作洪，朱炎昌，雷霆．神经生长因子受体在垂体腺瘤中的表达．临床与实验病理学杂志，2000，16：28-30．
24．张作洪，朱炎昌，雷霆．神经生长因子对体外培养的垂体泌乳素细胞的抑制作用．中华内分泌代谢杂志，2000，16：115-117．
25. Missale C, Losa M, Boroni F, et al. Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas. Br J of Cancer, 1995, 72: 1397-1399.
2. Melmed S. Pathogenesis of pituitary tumors [J]. Endocrinol Metab Clin North Am, 1999, 28:1-12.
3. Missale C, Fiorentini C, Finardi, et al. Growth factors in pituitary tumors. Pituitary, 1999, 1:153-158.
4．张龙，雷霆，薛德麟．EGF、TGF-α及其受体在垂体瘤中的表达．癌症，2000，19：944
5. Heaney AP, Horwitz GA, Wang Z, et al. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis [J]. Nat Med, 1999, 5: 1317-1321.
6. Zhang X, Horwitz GA, Prezant TR, et al. Structure, expression and function of human pituitary tumor transforming gene (PTTG) [J]. Mol Endocrinol, 1999, 13: 156-166.
7．郭常利，吴瑜，王兰，等．PCNA、P16、TGF-β1蛋白表达与垂体腺瘤侵袭性的关系．中国临床神经科学，2001，9：237-239．
8. Levi-Montalcini R. The nerve growth factor 35 years later[J]. Science, 1987, 237: 1154-1162.
9. Patterson JC, Childs GW. Nerve growth factor and its receptors in the anterior pituitary. Endocrinology, 1994, 135: 1689-1696.
10. Missale C, Boroni F, Sigala S, et al. Nerve growth factor in the anterior pituitary: Localization in mammotroph cells and cosecretion with prolactin by a dopamine-regulated mechanism. Pro Natl Acad Sci, 1996, 93:4240-4245.
11. Burnham P, Conner JM, Varon S, et al. Colocalization of NGF and TSH-like immunoreactivity in cultures of adult rat anterior pituitary cells. J Neurosci Res, 1995, 41:73-78.
12. Baker DL, Molemaar WM, Trojanowski JQ, et al. Nerve growth factor receptor in peripheral and central neuroectodermal tumors, other pediatric brain tumors and during development of the adrenal gland. Am J Pathol, 1991,139: 115-122.
13. Azar C, Scavarda NJ, Reynolds CP, et al. Multiple defects of the nerve growth factor receptor in human neuro-blastomas. Prog Clin Biol Res, 1991, 366:219-226.
14. Frade JM, Rodriguez-Tebar A, Barde YA. Induction of cell death by endogenous NGF through its P75 receptor [J]. Nature, 1996,383:166.
15. Zhu ZW, Friess H, Fabio F, et al. Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer. J Clin Oncol, 1999, 17: 2419-2428.
16. Sortino MA, Condorelli F, Vancheri C et al. Mitogenic effect of nerve growth factor (NGF) in LNCaP prostate adenocarcinoma cells: Role of the high-and low-affinity NGF receptors. Mol Endocrinol, 2000, 14: 124-136.
17. Zhu ZW, Friess H, Wang L, et al. Down-Regulation of nerve growth factor in poorly differentiated and advanced human esophageal cancer. Anti-cancer Research, 2000,20: 125-132.
1．王忠诚主编．神经外科学[M]．第一版．武汉：湖北科技出版社，1998，489．
2. Soule SG, Powell M, Jacobs HS. Prolactinomas resistant to dopamine agonists: Insights into pathogensis and therapy. Curt Opin Obstet Gynecol, 1994, 6:393-397.
3．张作洪，朱炎昌，雷霆．神经生长因子受体在垂体腺瘤中的表达．临床与实验病理学杂志，2000，16 28-30．
4．张达青，胡绍文主编．下丘脑-垂体疾病[M]．北京：科学技术文献出版社，2001，443．
5. Knosp E, Steiner E, Kitz K, et al. Pituitary adenomas with invasive of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery, 1993, 33: 610-617.
6. Meij BP, Lopes MB, Ellegala DB, et al. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery[J]. J neurosurg 2002, 96:195-208.
7. Levi-Montalcini R. The nerve growth factor 35 years later[J]. Science, 1987, 237: 1154-1162.
8. Klein R, Jing S, Nanduri V et al. The trk Proto-oncogene encodes a receptor for nerve growth factor. Cell, 1991; 65:189-197.
9. Hempstead BL, Martin-Zanca D, Kaplan DR, et al. High-affinity NGF binding requires coexpression of the trk protooncogene and Low-affinity NGF receptor. Nature (Lond), 1991, 350:678～683.
10. Maliartchouk S, Saragovi U. Optimal nerve growth factor trophic signals mediated by synergy of trkA and p75 receptor specific ligands. J Neurosci, 1997, 17:6031～6037.
11．郭丽英，周元聪．神经生长因子与细胞凋亡．生命的化学，1999；2：56～58．
12．张龙，雷霆，薛德麟．垂体瘤中EGF TGF-α及其受体的表达．中国肿瘤临床，2000；27：805-806．
13. Fukui S, Otani N, Nawashiro H, et al. Nuclear accumulation of basic fibroblast growth factor as a predictor for the recurrence of pituitary adenomas. J Neurooncol, 2002, 57:221-9.
14．张雪宝，陆天才，李锋，等．神经生长因子及其受体在宫颈原位癌中的表达．临床与实验病理学杂志，2003；19：145-148．
15. Krygiet s, Djakiew D. Neurotrophin recepotr p75(NTR) suppresses growth and nerve growth factor-mediated metastasis of human prostate cancer cells. Int J Cancer, 2002, 98:1-7.
16. Van Dierendonck JK, Wijsman JH, Keijzer R, et al. Cell cycle-related staining patterns of anti-proliferating cell nuclear antigen monoclonal antibodies. Am J Pathol, 1991, 138:1165-1172.
17. Hsu DW, Hakim F, Biller BMK, et al. significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence [J]. J neurosurg, 1993, 78:753-761.
18. Thaper K, Kovacs KT, Scheithauer BW, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-I antibody [J]. Neuro surgery, 1996, 38:99-107.
19. Molitch ME, Elton RL, Blackwell RE, et al. Bromocriptine as primary therapy for prolactin-secting macroadenomas: Results of a prospective multi-center study. J Clin Endocrinol Metab, 1985, 60:698.
20．张作洪，朱炎昌，雷霆．神经生长因子受体在垂体腺瘤中的表达．临床与实验病理学杂志，2000，16：28-30．
21. Pellegrini I, Rasolonjanahary R, Gunz G, et al. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab, 1989, 69:500-509.
22. Dinicola AF. Letter: Nerve growth factor and neuroblastoma. J Pediatr, 1976, 89: 517.
23. Watanable T, Katayama Y, Kimura S, et al. Control of proliferation and survival of C6 glioma cells with modification of the nerve growth factor autocrine system. J Neurooncol, 1999,41:121-128.
24. Missale C, Boroni F, Losa M, et al. Nerve growth factor suppresses the transforming phenotype of human prolactinomas. Prac Natl Acad Sci, 1993, 90:7961-7965.
25. Dobrowsky RT, Wether MH, Castellino AM, et al. Activation of the sphingomyelin cycle through the low affinity neurotrophin receptor. Science 265:1596-1599.
26. Kim M-Y, Linardic C, Obeid L, et al. Identification of sphingomyelin tumover as an effector mechanism for the action of tumor necrosis factor alpha and gamma interferon. J Biol Chem, 266:484-489.
27. Obeid LM, Linardic CM, Karolak LA, et al. Programmed cell death induced by ceramide. Science, 259:1769-1771.
28. Sigala S, Faraoni I, Botticini D, et al. Suppression of telomerase, reexpression of KAI1, and abrogation of tumorigenicity by nerve growth factor in prostate cancer cell lines. Clin Cancer Res. 1999, 5:1211-8.
29．张继红，李爱敏，张锦华．激活NGF／trkA信号传导通路引起NB细胞良性分化的研究．肿瘤防治杂志，2004，11：897-912．
1. Prasad KN, Hovland AR, Nahreini P, et al. Differentiation genes: are they primary targets for human carcinogenesis? Exp Biol Med, 2001, 226: 805-813.
2. Leszczyniecka M, Roberts T, Dent P, et al. Differentiation therapy of human cancer: basic science and clinical applications. Pharmacol Ther, 2001, 96: 1556-1561.
3. Anderson DJ. Molecular control of cell fate in neural crest: the sympathoadenal lineage. Annu Rev Neurosci, 1993, 16: 129-158.
4. Greene LA and Tischler AS. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor[J]. PNAS, 1976, 73: 2424-2428.
5. Yaeger MJ, Koestner A, Marushige K, et al. The reverse transforming effect of nerve growth factor on five human neurogenic tumor lines: in vitro results. Acta Neuropathol, 1991, 83:72～80
6. Mitchner NA, Garlick C, Steimnetz RW, et al. Differential regulation and action of estrogen receptors alpha and beta in GH3 cells. Endocrinology, 1999, 140: 2651-2658.
7. Missale C, Boroni F, Sigala S, et al. Nerve growth factor directs differentiation of the bipotential cell line GH3 into the mammotroph phenotype. Endocrinology, 1994, 135:220-228.
8．吴楠，查锡良．肿瘤细胞的诱导分化．生命的化学，2004，24：496-499．
9．汤钊猷主编．现代肿瘤学．肿瘤逆转．第1版．上海：上海医科大学出版社，1993．157-167
10. Kovacs K, Stefaneanu L, Horvath E, et al. Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy, Case report. J Neurosurg, 1995, 82: 886-890.
11. Missale C, Boroni F, Losa M, et al. Nerve growth factor suppresses the transforming phenotype of human prolactinomas. Proc Natl Acad Sci, 1993, 7961-7965.
12．高强，董倩，吕振华，等．转神经生长因子基因诱导神经母细胞瘤分化的研究．中华小儿外科杂志，2005，26：34-37．
13. Marushige Y, Marushige K, Koestner A. Growth inhibition of anaplastic glioma cells by nerve growth factor. Anticancer Res, 1992, 12: 2069-2073.
14．初明，胡志强，魏兰兰，等．白黎芦醇对垂体腺瘤GH3细胞生长及其分子机制的研究．中华医学杂志，2003，83：2004-2006．
15．李秋营，宋补昌，姚汝琳，MTT还原法与BrdU标记法检测2BS增殖活性比较．山西医科大学学报，2002，33：79-80．
16. Pestell RG, Albanese C, Reutens AT, et al. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocrine Rev, 1999, 20: 501-534.
17. Missale C, Codignola A, Sigala S, et al. Nerve growth factor abroagates the tumorigenicity of human small cell lung cancer cell lines. Proc Natl Acad Sci, 1998, 95: 5366-5371.
18. Miyasaka T, Sternberg DW, Miyasaka J, et al. Nerve growth factor stimulates protein tyrosine phosphorylation in PC-12 pheochromocytoma cells. Proc Natl Acad Sci, 1991, 88: 2653-2663.
19．关新民主编．医学神经生物学，第三章：受体，北京：人民卫生出版社，2002，63-65．
20. Walch ET, Marchetti D. Role of neurotrophins and neurotrophins receptors in the in vitro invasion and heparanase production of human prostate cancer cells. Clin Exp Metastasis. 1999, 17: 307-314.
21. Zhu ZW, Friess H, Wang L, et al. Nerve growth factor exerts differential effects on the growth factor as a mitogen for a pancreaticcancer cells. Clin Cancer Res, 2001, 7: 105-112.
22．佟海侠．神经营养因子及其受体在神经母细胞瘤中的作用．国外医学儿科学分册，2000，27：65-68．
23．折晓宁，陈杰，刘彤华，等．高亲和性神经生长因子受体对神经生长因子诱导 神经母细胞瘤细胞分化的影响．中华病理学杂志，2000，29：196-199．
24. Brann AB, Scott R, Neuberger Y, et al. Ceremide signaling downstream P75 neurotrophin receptor mediates the effects of nerve growth factor on outgrowth of cultured hippocampal neurons. J Neurosci, 1999, 19:8199-8206.
25. Encinas M, Iglesias M, Llecha N, et al. Extracellular-regulated kinases and phosphatidylinositol 3-kinase are involved in brain-derived neurotrophic factor-mediated survival and neuritogenesis of the neuroblastoma cell line SH-SY5Y. J Neurochem, 1999, 73:1409-1421.
1. Molitch ME. Disorders of prolatin section. Endocrinol Metab Clin NAmer, 2001, 30:585-610.
2. Decamilli P, Macconi D, Spada A, et al. Dopamine inhibits adenylate cyclase in human prolactin-secreting pituitary adenomas. Nature, 1979, 278:252-254.
3. Soule SG, Powell M, Jacobs HS. Prolactinomas resistant to dopamine agonists: insights into pathogenesis and therapy. Curr opin Obstet Gynecol, 1994, 6:393-397.
4. Monsma FJ, McVittie LD, Gerfen CR, et al. Multiple D2 dopamine receptors produced by alternative RNA splicing. Nature, 1989, 342:926-929.
5. Senogles SE. The D2 dopamine receptor isoforms signal through distinct Giα proteins to inhibit adenylyl cyclase. J Biol Chem, 1994, 269:23120-23127.
6. Vallar L, Vicentini LM, Meldolesi J, et al. Inhibition of inositol phosphate production is a late, Ca~(2+)-dependent effect of D2 dopaminergic receptor activation in rat lactotroph cells. J Biol Chem, 1988, 263:10127-10134.
7. Iaccarino C, Samad TA, Mathis C, et al. Control of lactotroph proliferation by dopamine: essential role of signaling through D2 receptors and ERKS. PNAS, 2002, 99:14530-14535.
8. Molitch ME. Dopamine resistance of prolactinomas. Pituitary, 2003, 65:19-27.
9. Kanasaki H, Fukunaga K, Takahashi, et al. Involvement of Mitogen-actived protein kinase activation in bromocriptine-induced apoptosis in rat GH3 cells. Biol of Reproduction, 2000, 62:1486-1494.
10. Missale C, Castelletti L, Boroni F, et al. Epidermal growth factor induces the functional expression of dopamine receptors in the GH3 cell line. Endocrinology. 1991, 128:13-20.
11. Pellegrini-Bouiller I, Morange-Ramos I, Barlier A, et al. Pit-1 gene expression in human lactotroph and somatotroph pituitary adenomas is correlated to D2 receptor gene expression. J Clin Endocrinol Metab. 1996, 81: 3390-6.
12．张作洪，朱炎昌，雷霆．神经生长因子受体在垂体腺瘤中的表达．临床与实验病理学杂志，2000，16：28-30．
13. Scillitani A, Dicembrino F, Di Fazio P, et al. In vivo visualization of pituitary dopaminergic receptors by iodine-123 methoxybenzamide (IBZM) correlates with sensitivity to dopamine agonists in two patients with macroprolactinomas. J Clin Endocrinol Metab, 1995, 80: 2523-2525.
14. Missale C, Nash SR, Robinson S, et al. Dopamine receptors: from structure to function. Physiol Rev, 1998, 78: 189-225.
15. Guivarc'h D, Vincent JD, Vernier P, et al. Alternative splicing of the D2 dopamine receptor messenger ribonucleic acid is modulated by activated sex steroid receptors in the MMQ prolactin cell line. Endocrinology. 1998, 139:4213-4221.
16. Missale C, Losa M, Sigala S, et al. Nerve growth factor controls proliferation and progression of human prolactinoma cell lines through an autocrine mechanism. Mol Endocrinol., 1996, 10: 272-85.
17. Yoon SO, Casaccia-Bonnefil P, Carter B, et al. Competitive signaling between TrkA and p75 nerve growth factor receptors determines cell survival. J Neurosci, 1998, 18: 3273-81
18．尹方明．P75和TrkA：两种NGF受体系．国外医学神经病学神经外科学分册，1997．24：205-208．
1. Soule SG, Powell M, Jacobs HS. Prolactinomas resistant to dopamine agonists: Insights into pathogensis and therapy. Curr Opin Obstet Gynecol, 1994, 6:393-397.
2. Friedman E, Adams EF, Hoog A, et al Normal structural dopamine type 2 receptor gene in prolactin-secreting and other pituitary tumors. J Clin Endocrinol Metab, 1994, 78(3): 568-74.
3. Liu JC, Baker RE, Sun C, et al. Activation of Go-coupled dopamine D_2 receptors inhibits ERK1/ERK2 in pituitary cells. A key step in the transcriptional suppression of the prolactin gene. J Biol Chem, 2002, 277:35819-35825.
4. Mark E., Molitch. Dopamine resistance of prolactinomas. Pituitary, 2003, 6:19-27.
5. Cannavo S, Bartolone L, Blandino A, et al. Shinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline. J Endocrinol Invest, 1999, 22: 306-309.
6. Delgrange E, Crabbe J, Donckier J. Late development of resistance to bromocriptine in a patient with macroprolactinoma. Horm Res, 1998, 49:250-253.
7. Hurel SJ, Haris PE, Mcnicol AM, et al. Metastatic prolactinoma: effect of octreotide, cabergoline, carboplactin and etoposide; immunocytochemical analysis of proto-oncogene expression. J Clin Endocrinol Metab, 1997,79:2962-2965.
8. Webster J, Piscitelli G, Polli A,et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med, 1994, 331: 904-909.
9. DiSarno A, Landi ML, Cappabianca P, et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: Prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab, 2001,86: 5256-5261.
10. Freda PU, Andreadis CI, Knandji AG, et al. Long-term treatment of prolactin-secreting macroadenomas with pergolide. J Clin Endocrinol Metab, 2000, 85:8-13.
11.Colao A, DiSarno A, Landi ML, et al. Macroprolactinoma shinkage during cabergoline treatments is greater in naive patients than in patients pretreated with other dopamine agonists: A prospective study in 110 patients. J Clin Endocrinol Metab, 2000, 85: 2246-2252.
12. Pellegrini I, Rasolonjanahary R, Gunz G, et al. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab, 1989, 69: 500-509.
13. Caccavelli L, Feron F, Morange I, et al. Decreased expression of the two D_2 dopamine receptor isoforms in bromocriptine-resistance prolactinoma. Neuroendocrinol, 1994, 60:314-322.
14. Caccavelli L, Morange-Ramos I, Kordon C, et al. Alteration of Ga subunits mRNA levels in bromocriptine-resistant adenomas. J Neuroendocrinol, 1996, 8:737-746.
15. Colao A, DiSarno A, Samacchiaro F, et al. Prolactinoma resistant to standard dopamine agonists respond to chronic cabergolione treatment. J Clin Endocrinol Metab, 1997, 82:876-883.
16. Lamberts S, Verleun T, Hofland L, et al. Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells. J Clin Endocrinol Metab. 1986, 63: 1342-1347.
17. Prior JC, Cox TA, Fairholm D, et al. Testosterone-related exacerbation of a prolactin-producing macroadenoma: Possible role for estrogen. J Clin Endocrinol Metab, 1987,64,391 -394.
18. Missale C, Boroni F, Losa M, et al. Nerve growth factor suppresses the transforming phenotype of human prolactinomas. Prac Natl Acad Sci, 1993, 90:7961-7965.
19. Missale C, Losa M, Boroni F, et al. Nerve growth factor and bromocriptine: A sequential therapy for human bromocriptine-resistant prolactinomas. Brit J Cancer, 1995,72: 1397-1399.
20. Fiorentini C, Guerra N, Facchetti M, et al. Nerve growth factor regulates dopamine D2receptor expression in prolactinoma cell lines via p75 -mediated activation of nuclear factor-κB. Mol Endocrinol, 2002, 16: 353-366.
1. Spada A, Lania A. Growth factors and human pituitary adenoma. Mol Cell Endocrinol. 2002, 197:63-68.
2. Chaidarun SS, Eggo MC, Sheppard MC, et al. Expression of epidermal growth factor (EGF), its receptor, and related oncoprotein (erbB-2) in human pituitary tumors and response to EGF in vitro. Endocrinology, 1994, 135:2012-2021.
3. Onguru O, Scheithauer BW, Kovacs K, et al. Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas. Mol Pathol, 2004, 17:772-780.
4. LeRiche VK, Asa SL, Ezzat SJ, et al. Epidermal growth factor and its receptor (EGFR) in human pituitary adenomas: EGFR correlates with tumor aggressiveness. Clin Endocrinol Metab, 1996, 81: 656-662.
5. Theodoropoulou M, Arzberger T, Gruebler Y, et al. Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells. J Endocrinol, 2004, 183: 385-394.
6．张龙，雷霆，薛德麟．表皮生长因子及染料木黄酮对垂体瘤细胞增殖的调节．同济医科大学学报，2001，30：131-133．
7. McCabe CJ, Khaira JS, Boelaert K, et al. Expression of pituitary tumor transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumor behaviour. Clin Endocrinol, 2003, 58:141-150.
8. Fukui S, Otani N, Nawashiro H, et al. Nuclear accumulation of basic fibroblast growth factor as a predictor for the recurrence of pituitary adenomas. J Neurooncol, 2002, 57: 221-229.
9．文路，陈凌，刘运生．碱性成纤维细胞生长因子与垂体腺瘤增殖及侵袭能力的关系．湖南医科大学学报，2001，26：466-468．
10. Fukui S, Otani N, Nawashiro H, et al. Subcellular localization of basic fibroblast growth factor and fibroblast growth factor receptor-1 in pituitary adenomas. Brain Tumor Pathol. 2002, 19: 23-29.
11. Crnauer MV, Schulz WA, Seifert HH, et al. Fibroblast growth factors and their receptors in urological cancers: basic research and clinical implications. Eur Urol, 2003, 43: 309-319.
12. Mignatti P, Morimoto T, Rifkin DB, et al.. In vitro angiogenesis on the human amniotic membrane: requirement of basic fibroblast growth factor induced proteinases [J]. J Cell Biol, 1989, 108:617 - 682.
13. Kawamoto H, Uozumi T, Kawamoto K, et al. Type Ⅳ collagenaseactivity and cavernous sinus invasion in human pituitary adenomas [J]. Acta Neurochir (Wien), 1996, 138: 390-395.
14. Sakarnoto H, Mori M, Taria M, et al. Transforming gene frorn human stomch cancers and a noncancerous portion of stomach mucosa [J]. Proc Natl Acad Sci, 1986, 83: 3997-4001.
15．郭常利，吴瑜，王兰，等．PCNA、P16、TGF-β1蛋白表达与垂体腺瘤侵袭性的关系．中国临床神经科学，2001，9：237-239．
16．王连刚，王喜青，武毅军等．表皮生长因子、转化生长因子-α及其受体在人垂体腺瘤组织中的表达，细胞与分子免疫学杂志，2000，16：156-158．
17. McAndrew J, Paterson AJ, Asa SL,. et al. Targeting of transforming growth factor-alpha expression to pituitary lactotrophs in transgenic mice results in selective lactotroph proliferation and adenomas. Endocrinology, 1995,136: 4479-4488.
18. Ramsdell JS. Transforming growth factor-alpha and-beta are potent and effective inhibitors of GH4 pituitary tumor cell proliferation. Endocrinology, 1991, 128: 1981-1990.
19. Fukui S, Otani N, Nawashiro H, et al. The association of the expression of vascular endothelial growth factor with the cystic component and haemorrhage in pituitary adenoma. J Clin Neurosci, 2003, 10: 320-324.
20．沈晓黎，雷霆，万锋，等．VEGF及其受体KDR在垂体腺瘤中的表达与肿瘤血管形成的关系．肿瘤防治研究，2005，32：8-10．
21. Lohrer P, Gloddek J, Hopfner U, et al. Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro. Neuroendocrinology, 2001, 74: 95-105.
22. Missale C, Boroni F, Sigala S, et al. Nerve growth factor in the anterior pituitary: localization in mammotroph cells and cosecretion with prolactin by a dopamine-regulated mechanism. Pro Natl Acad Sci, 1996, 93:424-425.
23．张作洪，朱炎昌，雷霆．神经生长因子受体在垂体腺瘤中的表达．临床与实验病理学杂志，2000，16：28-30．
24．张作洪，朱炎昌，雷霆．神经生长因子对体外培养的垂体泌乳素细胞的抑制作用．中华内分泌代谢杂志，2000，16：115-117．
25. Missale C, Losa M, Boroni F, et al. Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas. Br J of Cancer, 1995, 72: 1397-1399.